Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

Science China. Life Sciences
Ligong LuYou-Wen He


The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARS-CoV-2 infection is a critical determinant for patients' outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent p...Continue Reading


Jul 20, 2011·Proceedings of the National Academy of Sciences of the United States of America·Claudia FerraraJörg Benz
Jul 30, 2014·Biochemical and Biophysical Research Communications·Sheng-Fan WangJason C Huang
May 11, 2016·Journal of Proteome Research·Noortje de HaanManfred Wuhrer
Nov 4, 2017·Science·Leah C KatzelnickEva Harris
Dec 13, 2019·Journal of Virology·Yushun WanFang Li
Feb 25, 2020·Microbes and Infection·Jason A Tetro
Feb 28, 2020·JAMA : the Journal of the American Medical Association·Lan LanHaibo Xu
Mar 22, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Li GuoJianwei Wang
Mar 29, 2020·JAMA : the Journal of the American Medical Association·Chenguang ShenLei Liu
Mar 30, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juanjuan ZhaoZheng Zhang
Apr 3, 2020·Vaccines·Jinyong ZhangQuanming Zou
Apr 7, 2020·Trends in Immunology·Shibo JiangLanying Du
Apr 8, 2020·Proceedings of the National Academy of Sciences of the United States of America·Kai DuanXiaoming Yang
Apr 8, 2020·The Journal of Clinical Investigation·Evan M BlochAaron Ar Tobian
Apr 9, 2020·The New England Journal of Medicine·Yan ZhangShuyang Zhang
Apr 14, 2020·Journal of Korean Medical Science·Jin Young AhnJun Yong Choi
Apr 16, 2020·Journal of Medical Virology·Mingxiang YeTangfeng Lv
Apr 25, 2020·Nature Medicine·Waradon SungnakUNKNOWN HCA Lung Biological Network
Apr 25, 2020·Cell·Dongwan KimHyeshik Chang
May 1, 2020·Nature Medicine·Quan-Xin LongAi-Long Huang
May 6, 2020·Nature Communications·Chunyan WangBerend-Jan Bosch
May 12, 2020·Frontiers in Microbiology·Longping V TseRalph S Baric

❮ Previous
Next ❯


Jun 29, 2021·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Suchet SachdevManoranjan Mahapatra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Enhancement

Antibody-dependent enhancement of viral infection is the entry of virus into host cells mediated by antiviral antibodies interacting with Fc or complement receptors. This has been most extensively observed with the dengue virus. Find the latest research on antibody-dependent enhancement here.